|Year : 2017 | Volume
| Issue : 1 | Page : 11-12
Specificity of 68Ga-PSMA PET/CT for prostate cancer - myths and reality
Consultant Nuclear Medicine and PET/CT, KIMS-DDNMRC, KIMS hospital North Block, Anayara P.O, Thiruvananthapuram, Kerala, India
|Date of Web Publication||17-Jan-2017|
Consultant Nuclear Medicine and PET/CT, KIMS-DDNMRC, KIMS hospital North Block, Anayara P.O, Thiruvananthapuram, Kerala
Source of Support: None, Conflict of Interest: None
| Abstract|| |
68Ga-PSMA ligand PET/CT for imaging prostate cancer is a novel imaging technique, which is rapidly gaining popularity. Sufficient evidence has been accumulated in literature regarding the usefulness of 68Ga-PSMA PET/CT in prostate cancer. Recently literature regarding the localization of 68Ga-PSMA PET/CT imaging in non-prostatic malignancies is also published, thus questioning the specificity of the tracer with regards to prostate cancer. This commentary tries to address the issue of specificity of 68Ga-PSMA PET/CT and its relevance in imaging prostate cancer.
Keywords: 68Ga PSMA, prostate cancer, specificity
|How to cite this article:|
Sasikumar A. Specificity of 68Ga-PSMA PET/CT for prostate cancer - myths and reality. Indian J Nucl Med 2017;32:11-2
The introduction of 68Ga-PSMA-11 for imaging prostate cancer is one of the most remarkable developments in nuclear medicine in the recent years. It is not surprising that the use of this new radiopharmaceutical for PET-CT imaging of prostate cancer worldwide has happened in a very short span of time. This is probably due to the high prevalence of prostate cancer and the absence of a suitable PET tracer for this indication. Prostate specific membrane antigen (PSMA) is a metalloenzyme, a type II membrane glycoprotein with 19-aminoacid intracellular, 24 amino acid transmembrane and 707 amino acid extracellular domain and having two major enzymatic actions that is folate hydrolase and NAALDase, and in both cases the enzymatic role is to release the terminal glutamate residue, which acts as a neurotransmitter. Initially, it was detected to be expressed in prostate and thus was named as PSMA However, eventual histopathological studies confirmed its physiological expression at non-prostatic sites including duodenal epithelial (brush border) cells, salivary glands, lacrimal glands, proximal tubule cells in the kidney etc. While the most documented over expression of PSMA is in prostate adenocarcinoma, the enzyme is also over-expressed in renal cell carcinoma, glioma, hepatocellular carcinoma and in the neovasculature of several other solid tumors. The radiopharmaceutical, 68Ga-PSMA-11, is a small molecular weight (~1000 Da) radiolabelled enzyme inhibitor that targets the extracellular portion of the enzyme and hence is suitable for imaging any tissues that over express PSMA.
Although histopathological evidence of PSMA over expression in non-prostatic malignancies is documented in literature, 68Ga-PSMA-11 PET/CT imaging started to be used in a major way for imaging prostate cancer. Sufficient evidence has been accumulated in literature regarding the usefulness of 68Ga-PSMA-11 PET/CT in prostate cancer. Potential applications of this tracer in prostate cancer management include identification of suspected primary site, helping in PET based targeted biopsy, staging, recurrence evaluation as well as for radiotherapy planning.
In parallel, the localization of 68Ga-PSMA-11 PET/CT imaging in non-prostatic malignancies is also being reported in literature. These include clear cell renal carcinoma, breast cancer, gliomas, primary hepatocellular carcinoma, differentiated thyroid cancer, and more indications are getting added., These reports have cast a shadow on the specificity of 68Ga-PSMA-11 for prostate cancer. When it comes to medical imaging, specificity is not the only important factor; in which case 18F-FDG would not have become the 'molecule of the century' in nuclear medicine and not so widely successful in oncology.
68Ga-PSMA-11 PET/CT is the best available imaging tool in the management of prostate cancer. The expected sites of involvement like prostate gland, seminal vesicles, pelvic nodes and skeleton may not pose difficulties during interpretation of 68Ga-PSMA-11 PET/CT. Unusual sites of involvement have to be attended carefully while interpreting 68Ga-PSMA-11 PET/CT scan. This issue of the journal presents an article entitled 'Rare sites of metastases in Prostate cancer detected on 68Ga-PSMA PET/CT scan - A Case Series' describing three unusual sites of metastases (brain, penis and liver) from prostate cancer. While, histopathology to confirm metastasis from prostate cancer was done for liver and penile sites, the brain metastasis is assumed to be from prostate cancer. Like with any other nuclear medicine imaging, a careful and meticulous clinical history and correlative investigations will help in ascertaining the true nature of unusual sites of tracer avid lesions seen in 68Ga-PSMA-11 PET/CT. Histopathological evidence may be required from these unusual sites in those cases where an alternate diagnosis would change the management strategy in the index case. The pit falls of 68Ga-PSMA-11 uptake in non malignant conditions are also getting documented for e.g. the tracer is taken up in Paget's disease  further questioning its specificity and warranting caution in the interpretation of tracer avid bone lesions.
To conclude, though 68Ga-PSMA-11 PET/CT is not unique to prostate cancer it is the best and most specific tracer available for imaging of prostate cancer as of now. An understanding of the possible conditions of uptake in 68Ga-PSMA-11 PET/CT will help the nuclear medicine physician to minimize reporting fallacies. Whenever an unusual site of involvement is noted in the 68Ga-PSMA-11 PET/CT, a careful history and correlative imaging will help resolve the reporting dilemma in most cases. In still unsettled cases and where a change in management is expected based on the unusual site of involvement, histopathological confirmation is warranted. 68Ga-PSMA-11 PET/CT is in its early stages and is eventually expected to make a definitive mark in diagnostic nuclear medicine.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Pillai MRA, Nanabala R, Joy A, Sasikumar A. Knapp FF (Jr), Radiolabeled Enzyme Inhibitors Binding Agents Targeting PSMA: Effective Theranostic Tools for Imaging and Therapy of Prostate Cancer. Nucl Med Biol 2016;43:692-720.
Silver DA, Pellicer J, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-5.
Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999;5:2674-81.
Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al.
The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015;42:197-209.
Schwenck J, Tabatabai G, Skardelly M, Reischl G, Beschorner R, Pichler B, et al. In vivo
visualization of prostate-specific membrane antigen in glioblastoma. Eur J Nucl Med Mol Imaging 2015;42:170-71.
Sasikumar A, Joy A, Nanabala R, Pillai MR, Thomas B, Vikraman KR. (68)Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma.. Eur J Nucl Med Mol Imaging 2016;43:795-6.
Artigas C, Alexiou J, Garcia C, Wimana Z, Otte FX, Gil T, et al.
Paget bone disease demonstrated on (68)Ga-PSMA ligand PET/CT. Eur J Nucl Med Mol Imaging 2016;43:195-6.